The startup develops neo-RNA therapeutics that utilize data-driven liver cancer diagnostic technology to enhance macrophage immuno-oncology and RNA regulator-targeted treatments. By enabling early detection of liver cancer, the company aims to improve treatment outcomes through increased sensitivity and specificity in diagnosis.
Funding
Funding not disclosed
Founders
Product
Problem
Liver cancer is often diagnosed at advanced stages due to a lack of effective early detection methods, resulting in limited treatment options and poor patient outcomes. Current diagnostic approaches may lack the sensitivity and specificity needed for timely intervention.
Solution
Neornat develops RNA-based therapeutics targeting liver cancer by enhancing macrophage immuno-oncology and RNA regulator-targeted treatments. The company leverages data-driven diagnostic technology to improve the early detection of liver cancer, enabling more effective treatment strategies. Their approach involves using GalNAc-conjugated antisense microRNA (miRNA) to target and suppress CD47, activating macrophages for an enhanced anti-tumor immune response. By delivering microRNA drugs specifically to the liver, Neornat aims to improve treatment outcomes and patient survival rates. The company is currently working towards submitting an IND application for their miRNA-based liver cancer therapy.
Target Audience
The primary target audience includes patients with or at risk of developing liver cancer, as well as clinicians and researchers in the fields of oncology, RNA therapeutics, and drug development.
Features
- Development of neo-RNA therapeutics for liver cancer treatment.
- Utilizes GalNAc-conjugated let-7i-5p antisense microRNA (miRNA) for targeted drug delivery.
- Designed to inhibit CD47 and activate macrophages, enhancing the anti-tumor immune response.
- Focus on early detection and improved diagnostic sensitivity and specificity.
- Aims to submit an IND application for their miRNA-based therapy in the near future.
- Collaboration with other companies for RNA-based gene therapy development using non-viral gene delivery systems.